{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:18Z","timestamp":1790108778002,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.biopha.2024.116678","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T23:03:48Z","timestamp":1715036628000},"page":"116678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?"],"prefix":"10.1016","volume":"175","author":[{"given":"J.","family":"Cusato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Palermiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Lupia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Stroffolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"D'Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116678_bib1","unstructured":"WHO. 2023 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b#:\u223c:text=WHO%20estimates%20that%20296%20million,carcinoma%20(primary%20liver%20cancer)."},{"key":"10.1016\/j.biopha.2024.116678_bib2","doi-asserted-by":"crossref","unstructured":"Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 14(1):1-21, vii.","DOI":"10.1016\/j.cld.2009.11.009"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.116678_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1386-6532(05)00384-7","article-title":"Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention","volume":"34","author":"Lavanchy","year":"2005","journal-title":"J. Clin. Virol."},{"issue":"9663","key":"10.1016\/j.biopha.2024.116678_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2024.116678_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2024.116678_bib6","doi-asserted-by":"crossref","unstructured":"Nguyen M.H., Wong G., Gane E., Kao J.H., Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev.33(2).","DOI":"10.1128\/CMR.00046-19"},{"issue":"2","key":"10.1016\/j.biopha.2024.116678_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"EASL","year":"2017","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116678_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040382","article-title":"Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection","volume":"7","author":"Duwal","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2024.116678_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/psp4.12955","article-title":"Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population","volume":"12","author":"Kawuma","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"10.1016\/j.biopha.2024.116678_bib10","unstructured":"DrugBank. [2024\/04\/19]. Available from: https:\/\/go.drugbank.com\/drugs\/DB14126."},{"issue":"24","key":"10.1016\/j.biopha.2024.116678_bib11","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.3748\/wjg.v20.i24.7696","article-title":"Human genes involved in hepatitis B virus infection","volume":"20","author":"Zeng","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116678_bib12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/chromsci\/46.6.524","article-title":"A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients","volume":"46","author":"D'Avolio","year":"2008","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.biopha.2024.116678_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpba.2015.05.001","article-title":"A LC-MS method to quantify tenofovir urinary concentrations in treated patients","volume":"114","author":"Simiele","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"10.1016\/j.biopha.2024.116678_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/14656566.2016.1118056","article-title":"Pharmacotherapeutic options for hepatitis B","volume":"17","author":"Chen","year":"2015","journal-title":"Expert Opin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.116678_bib15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/MNH.0000000000000392","article-title":"Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug","volume":"27","author":"Chan","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"5","key":"10.1016\/j.biopha.2024.116678_bib16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11096-015-0132-1","article-title":"Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients","volume":"37","author":"Quesada","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2024.116678_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u00e2\u20ac\u00afweeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116678_bib18","first-page":"65","article-title":"Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?","volume":"19","author":"Calcagno","year":"2018","journal-title":"Pharm. J."},{"issue":"8","key":"10.1016\/j.biopha.2024.116678_bib19","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00705-022-05466-y","article-title":"Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B","volume":"167","author":"Boglione","year":"2022","journal-title":"Arch. Virol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116678_bib20","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00705-021-04992-5","article-title":"Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study","volume":"166","author":"Boglione","year":"2021","journal-title":"Arch. Virol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116678_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/omi.2022.0105","article-title":"Treating hepatitis B virus in times of COVID-19: the case for clinical pharmacogenomics research in tenofovir-induced kidney toxicity","volume":"26","author":"Thomford","year":"2022","journal-title":"OMICS"},{"issue":"1","key":"10.1016\/j.biopha.2024.116678_bib22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.4102\/sajhivmed.v22i1.1206","article-title":"Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid","volume":"22","author":"Decloedt","year":"2021","journal-title":"South Afr. J. HIV Med."},{"issue":"16","key":"10.1016\/j.biopha.2024.116678_bib23","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2217\/pgs-2017-0128","article-title":"Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients","volume":"18","author":"Rungtivasuwan","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.biopha.2024.116678_bib24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2217\/pgs.09.115","article-title":"Pharmacogenetics of tenofovir treatment","volume":"10","author":"Rodriguez-Novoa","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.biopha.2024.116678_bib25","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1086\/598507","article-title":"Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study","volume":"48","author":"Rodriguez-Novoa","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2024.116678_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001809","article-title":"Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study","volume":"12","author":"Mocroft","year":"2015","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.biopha.2024.116678_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QAI.0b013e31827ce4ee","article-title":"Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration","volume":"62","author":"Poizot-Martin","year":"2012","journal-title":"J. Acquir Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.biopha.2024.116678_bib28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12879-017-2497-3","article-title":"Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients","volume":"17","author":"Salvaggio","year":"2017","journal-title":"BMC Infect. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2024.116678_bib29","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/508546","article-title":"Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy","volume":"194","author":"Izzedine","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2024.116678_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/infdis\/jir215","article-title":"Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction","volume":"204","author":"Pushpakom","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2024.116678_bib31","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/cis772","article-title":"Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study","volume":"55","author":"Nishijima","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2024.116678_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147724","article-title":"A single-nucleotide polymorphism in ABCC4 Is associated with tenofovir-related beta2-microglobulinuria in thai patients with HIV-1 infection","volume":"11","author":"Likanonsakul","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.116678_bib33","doi-asserted-by":"crossref","unstructured":"Achhra A.C., Nugent M., Mocroft A., Ryom L., Wyatt C.M. Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments. Curr HIV\/AIDS Rep. 2;13(3):149-157.","DOI":"10.1007\/s11904-016-0315-y"},{"issue":"2","key":"10.1016\/j.biopha.2024.116678_bib34","first-page":"202","article-title":"Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients","volume":"20","author":"Cusato","year":"2019","journal-title":"Pharm. J."},{"issue":"6","key":"10.1016\/j.biopha.2024.116678_bib35","first-page":"514","article-title":"Clinical pharmacology of tenofovir clearance: a pharmacokinetic\/pharmacogenetic study on plasma and urines","volume":"16","author":"Calcagno","year":"2016","journal-title":"Pharm. J."},{"issue":"2","key":"10.1016\/j.biopha.2024.116678_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.diagmicrobio.2018.07.001","article-title":"Tenofovir alafenamide and tenofovir disoproxil fumarate are not transported by concentrative nucleoside transporter 2","volume":"94","author":"Cusato","year":"2019","journal-title":"Diagn. Microbiol Infect. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2024.116678_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FPC.0000000000000491","article-title":"Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans","volume":"33","author":"Mateza","year":"2023","journal-title":"Pharm. Genom."},{"issue":"9","key":"10.1016\/j.biopha.2024.116678_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/FPC.0000000000000482","article-title":"Proximal tubular dysfunction related to tenofovir in people living with HIV\/AIDS: a pharmacogenetic study","volume":"32","author":"Soares","year":"2022","journal-title":"Pharm. Genom."},{"issue":"2","key":"10.1016\/j.biopha.2024.116678_bib39","article-title":"Antiretroviral levels in the cerebrospinal fluid: the effect of inflammation and genetic variants","volume":"13","author":"Cusato","year":"2023","journal-title":"Diagn. (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2024.116678_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jac\/dkt339","article-title":"High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis","volume":"69","author":"Calcagno","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2024.116678_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FPC.0000000000000495","article-title":"Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV","volume":"33","author":"Cindi","year":"2023","journal-title":"Pharm. Genom."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224005626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224005626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:37:33Z","timestamp":1741030653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224005626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":41,"alternative-id":["S0753332224005626"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116678","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116678"}}